Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...

Antidepressant Drugs: Overview

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...

Management of Insomnia

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Psychotropic drug-dependent modulation of excitatory-inhibitory balance in the prefrontal cortex of rats exposed to acute footshock stress.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2025

Same author

Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations.

Frontiers in psychiatry·2024

Same author

Transcriptomic profiles in major depressive disorder: the role of immunometabolic and cell-cycle-related pathways in depression with different levels of inflammation.

Molecular psychiatry·2024

Same author

Ghrelin, Neuroinflammation, Oxidative Stress, and Mood Disorders: What Are the Connections?

Current neuropharmacology·2024

Same author

Early life adversities, psychopathologies and novel pharmacological strategies.

Pharmacology & therapeutics·2024

Same author

Molecular signatures of astrocytes and microglia maladaptive responses to acute stress are rescued by a single administration of ketamine in a rodent model of PTSD.

Translational psychiatry·2024

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Published on: April 26, 2024

The interaction between the internal clock and antidepressant efficacy.

Giorgio Racagni¹, Marco A Riva, Maurizio Popoli

¹Center of Neuropharmacology, Department of Pharmacological Sciences and Center of Excellence on Neurodegenerative Diseases, University of Milan, Milan, Italy.

International Clinical Psychopharmacology

|December 6, 2007

Summary

This summary is machine-generated.

Agomelatine, an antidepressant, resynchronizes sleep-wake cycles and shows antidepressant effects by acting on melatonergic and serotonin receptors. Its unique mechanism may involve synergistic action for treating depression.

More Related Videos

Animal Models of Depression - Chronic Despair Model (CDM)

Animal Models of Depression - Chronic Despair Model (CDM)

Published on: September 23, 2021

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Jul 11, 2026

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Published on: April 26, 2024

Animal Models of Depression - Chronic Despair Model (CDM)

Animal Models of Depression - Chronic Despair Model (CDM)

Published on: September 23, 2021

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Area of Science:

Neuroscience
Pharmacology
Psychiatry

Background:

Sleep disturbances and circadian rhythm dysregulation are linked to depression.
The suprachiasmatic nucleus regulates circadian rhythms via light, nonphotic pathways, serotonin, and melatonin.
Agomelatine is a novel antidepressant with a unique dual mechanism of action.

Purpose of the Study:

To explore the mechanism of action of agomelatine in the context of depression and circadian rhythms.
To investigate agomelatine's effects on melatonergic and serotonergic pathways.
To understand how agomelatine's receptor interactions contribute to its antidepressant efficacy.

Main Methods:

Agomelatine was administered to animal models.
Effects on neurotransmitter levels (noradrenaline, dopamine, serotonin) in the frontal cortex were measured.
Resynchronization of sleep-wake cycles in disrupted models was assessed.
Antidepressant effects were evaluated in various animal models of depression.

Main Results:

Agomelatine increased noradrenaline and dopamine in the frontal cortex, without affecting serotonin.
The drug successfully resynchronized disrupted circadian rhythms in animal models.
Agomelatine demonstrated significant antidepressant effects across multiple depression models.

Conclusions:

Agomelatine's efficacy in depression may stem from its ability to resynchronize circadian rhythms.
Its dual action as a melatonergic agonist and 5-HT2C antagonist is key to its therapeutic effect.
Potential synergy between melatonergic and serotonergic pathway modulation underlies agomelatine's antidepressant action.